GlaxoSmithKline plc (LON:GSK) received a GBX 1,600 ($20.66) price target from stock analysts at Morgan Stanley in a research report issued on Friday. The brokerage presently has a “sell” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 7.10% from the stock’s current price.

A number of other brokerages have also recently commented on GSK. J P Morgan Chase & Co reiterated a “neutral” rating and issued a GBX 1,750 ($22.60) price target on shares of GlaxoSmithKline plc in a research note on Saturday, May 20th. S&P Global set a GBX 1,500 ($19.37) price target on GlaxoSmithKline plc and gave the company a “sell” rating in a research note on Tuesday, June 6th. UBS AG set a GBX 1,600 ($20.66) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Deutsche Bank AG increased their price objective on GlaxoSmithKline plc from GBX 1,700 ($21.96) to GBX 1,720 ($22.21) and gave the company a “hold” rating in a report on Friday, May 12th. Finally, Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a report on Friday, June 2nd. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc presently has an average rating of “Hold” and a consensus price target of GBX 1,714.48 ($22.14).

GlaxoSmithKline plc (LON GSK) traded down 1.09% during midday trading on Friday, hitting GBX 1494.00. The stock had a trading volume of 5,910,086 shares. The stock’s market cap is GBX 73.03 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56. The company has a 50-day moving average of GBX 1,521.96 and a 200-day moving average of GBX 1,615.99.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/08/glaxosmithkline-plc-gsk-pt-set-at-gbx-1600-by-morgan-stanley.html.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga acquired 2,267 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, July 26th. The stock was acquired at an average cost of GBX 1,599 ($20.65) per share, for a total transaction of £36,249.33 ($46,815.61). Also, insider Patrick Vallance acquired 861 shares of GlaxoSmithKline plc stock in a transaction that occurred on Friday, July 14th. The stock was acquired at an average price of GBX 1,618 ($20.90) per share, with a total value of £13,930.98 ($17,991.71). Insiders purchased a total of 3,144 shares of company stock valued at $5,043,015 over the last quarter.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.